Phase I Trial of Nelfinavir and Bortezomib in Advanced Hematologic Malignancies.

Trial Profile

Phase I Trial of Nelfinavir and Bortezomib in Advanced Hematologic Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2014

At a glance

  • Drugs Bortezomib (Primary) ; Nelfinavir (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Adult T-cell leukaemia-lymphoma; Anaplastic large cell lymphoma; Cutaneous T cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Hodgkin's disease; Lymphoproliferative disorders; Mantle-cell lymphoma; Multiple myeloma; Mycosis fungoides; Peripheral T-cell lymphoma; Sezary syndrome; T cell lymphoma; T cell prolymphocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Dec 2013 Planned end date changed from 1 Mar 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
    • 10 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 26 Apr 2012 Planned number of patients changed from 18 to 24 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top